- Home
- LSF vs GOSS Comparison
LSF vs GOSS Comparison
Compare LSF & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | GOSS |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 41.7M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LSF | GOSS |
|---|---|---|
| Price | $4.74 | $0.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $6.00 | $4.19 |
| AVG Volume (30 Days) | 65.0K | ★ 15.6M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.28 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $49,889,286.00 | $48,471,000.00 |
| Revenue This Year | $90.82 | N/A |
| Revenue Next Year | N/A | $201.64 |
| P/E Ratio | $42.18 | ★ N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $1.96 | $0.14 |
| 52 Week High | $7.80 | $3.87 |
Technical Indicators
Market Signals| Indicator | LSF | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 78.13 | 35.94 |
| Support Level | $2.41 | $0.16 |
| Resistance Level | $5.89 | $0.36 |
| Average True Range (ATR) | 0.29 | 0.02 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 87.17 | 39.08 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).